Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 12/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29992497 | 1.00 | AKR1C3 (0.57) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 | |
| SCHEMBL29992573 | 0.93 | AKR1C3 (0.54) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 | |
| SCHEMBL29992543 | 0.93 | HTR6 (0.52) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 | |
| SCHEMBL30777149 | 0.90 | HTR6 (0.53) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 | |
| SCHEMBL29992485 | 0.90 | HTR6 (0.53) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 | |
| SCHEMBL29993260 | 0.89 | AKR1C3 (0.58) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 | |
| SCHEMBL29992699 | 0.88 | AKR1C3 (0.54) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 | |
| SCHEMBL29992755 | 0.86 | AKR1C3 (0.50) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 | |
| SCHEMBL14304584 | 0.86 | AKR1C3 (0.61) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 | |
| SCHEMBL16727061 | 0.85 | AKR1C3 (0.57) | AKR1C3HTR6AKR1C2L3MBTL1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254081-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2024-08-01 | — | — | US | disclosed |
| EP-4334285-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | Kare Chemical Technologies Inc. (CA) | 2024-03-13 | — | — | EP | disclosed |
| CN-117597329-A | Method for the catalytic synthesis of tryptamine and precursors thereof | 凯尔化学科技公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2022232931-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022232931-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | KARE CHEMICAL TECHNOLOGIES INC. (CA) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254081-A1 | CATALYTIC TRYPTAMINE PROCESSES AND PRECURSORS | HNMT, TPSB2, TPSG1 | AKR1C3 1859/4885HTR6 45/4885AKR1C2 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.